GS
MDGL icon

GTS Securities’s Madrigal Pharmaceuticals MDGL Stock Holding History

GTS Securities’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,900
Closed -$4.44M – 2932
2024
Q3 		$4.44M Buy
20,900
+7,700
+58% +$1.97M 0.01% 967
2024
Q2 		$3.7M Sell
13,200
-6,400
-33% -$1.52M 0.01% 1057
2024
Q1 		$5.23M Sell
19,600
-3,800
-16% -$895K 0.01% 832
2023
Q4 		$5.41M Buy
23,400
+9,800
+72% +$1.71M 0.01% 942
2023
Q3 		$1.99M Buy
+13,600
New +$2.56M ﹤0.01% 1523

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

GTS Securities's MDGL Position: Q4 2024 in Review

GTS Securities sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2024, closing a stake of 6,176 shares — an estimated $1.31M sold.

GTS Securities first reported a position in MDGL in Q3 2023 and held it in 5 quarters. The position peaked at $1.31M in Q3 2024. 283 funds tracked by Wall St. Rank hold MDGL as of Q4 2024.

  • GTS Securities reported no remaining Madrigal Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • GTS Securities sold 6,176 Madrigal Pharmaceuticals shares in Q4 2024, an estimated $1.31M.
  • GTS Securities first reported a position in Madrigal Pharmaceuticals in Q3 2023 and held it in 5 quarters.
  • GTS Securities's Madrigal Pharmaceuticals position peaked at $1.31M in Q3 2024.
  • 283 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2024.

Based on GTS Securities's 13F filing for Q4 2024, filed 18 Feb 2025.